Safety of home-based exercise for people with intermittent claudication: A systematic review

Alexander Waddell1, Sally Seed2, David R Broom1, Gordon McGregor1,3,4, Stefan T Birkett2 and Amy E Harwood1

Abstract

Intermittent claudication (IC) is a classic symptom of peripheral artery disease, with first line treatment being supervised exercise therapy (SET). Despite this, SET is frequently underutilised, and adherence is often poor. An alternative option are home-based exercise programmes (HBEP). Although HBEPs are well tolerated, to our knowledge, no research has assessed their safety. The aim of this review was to assess the safety of HBEPs in people living with IC. We performed an electronic search of the MEDLINE, CINAHL, and Cochrane Library databases. The main parameter of interest was complication rate, calculated as the number of related adverse events per patient-hours. Subanalysis was undertaken to determine differences in safety for studies that did and did not include pre-exercise cardiac screening, and for studies with exercise at low, moderate, and high levels of claudication pain. Our search strategy identified 8693 results, of which 27 studies were included for full review. Studies included 1642 participants completing 147,810 patient-hours of home-based exercise. Four related adverse events were reported, three of which were cardiac in origin, giving an all-cause complication rate of one event per 36,953 patient-hours. Three of these events occurred following exercise to high levels of claudication pain, and one occurred with pain-free exercise. One event occurred in a study without cardiac screening. Based on the low number of related adverse events, HBEPs appear to be a safe method of exercise prescription for people with IC. Our results strengthen the rationale for providing alternative exercise options for this population. PROSPERO Registration No.: CRD42021254581

Keywords
claudication, complication rate, exercise therapy, home-based exercise, peripheral artery disease (PAD), safety

Background

Peripheral artery disease (PAD) affects over 236 million people worldwide.1 Intermittent claudication (IC) is a classic symptom of PAD, defined as calf pain or discomfort induced by exertion which is relieved by rest.2 IC is associated with an increased risk of mortality,3 and reductions in quality of life,4 functional ability,5 and physical activity behaviour.6 National and international guidelines recommend supervised exercise therapy (SET) as first line treatment for IC.7,8 Structured SET has shown improvements in peak oxygen consumption, pain-free and maximal walking distances, and quality of life.9,10 Despite strong evidence demonstrating the benefits of SET, its availability, adherence, and uptake remain low,11–13 especially in the US, when compared to antplatelet therapy, statins, and smoking cessation.14 Commonly cited barriers include time constraints, travel difficulties, and other personal commitments.15,16

To improve the access and availability of exercise programmes for people with IC, studies have investigated the role of home-based exercise programmes (HBEP). Although HBEPs are well tolerated and have shown improvements in walking performance,17 to our knowledge, no research has assessed their safety. Supervised exercise therapy has already been deemed safe for those with IC, with a low complication rate and with no need for prior cardiac screening.18 Unlike SET in a clinical setting or
part of an exercise referral scheme, there is no direct supervision from a health or fitness professional when undertaking a HBEP, which may increase the risk of exercise-related complications and compromise safety. Some HBEPs involve remote exercise monitoring, such as with activity watches or telephone contact, which improves the effectiveness of HBEPs, but does not necessarily monitor participant safety.

The aim of this review, therefore, was to assess the safety of HBEPs in people living with IC by calculating a complication rate.

**Methods**

This review was conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The systematic review was registered with PROSPERO (Registration No.: CRD42021254581).

**Eligibility**

We included studies that investigated the effects of HBEPs in people diagnosed with symptomatic IC secondary to PAD (Fontaine II / Rutherford 1–3). Studies that included other PAD subgroups, such as asymptomatic individuals, were only included where specific data were obtained on the IC subgroup. We included studies examining HBEPs alone, in comparison to other forms of exercise or to nonexercise controls. Both randomised and nonrandomised studies were included. Studies were limited to those in humans and written in English. There was no restriction on publication date.

**Search**

We performed an electronic search of the MEDLINE, CINAHL, and Cochrane Library databases up to June 2021. Reference lists of retrieved studies were also examined along with ClinicalTrials.gov registrations for trials in progress. The search included MeSH terms and keywords relating to the topic of the review, which can be found in the online supplementary material. Examples include: ‘Peripheral Arterial Disease’, ‘intermittent claudication’, ‘PAD’, ‘home-based exercise’, ‘home-based training’, and ‘walking programme’.

**Data extraction and management**

Search results were first imported into the reference management software Endnote (version X9.3.3, Clarivate Analytics) for duplicate removal, before being transferred to Covidence (version v2698, Veritas Health Innovations) for screening. Titles and abstracts of imported studies were reviewed independently by two researchers (AW and SS), with conflicts being resolved by a third (AH). The full texts of included studies were subsequently reviewed and data were collected on the study population, number of participants, frequency, duration, and content of exercise sessions, number of adverse events, and drop out/loss to follow up. If data were unclear regarding adverse events or reasons for drop out, the authors were contacted for clarification. If no clarification was received, these studies were excluded, a decision based on the methods of Gommans et al.

**Outcomes**

The main outcome of interest was complication rate, calculated using Microsoft Excel as the number of adverse events deemed directly related to exercise participation, per patient-hours. The number of patient-hours was calculated as the number of participants multiplied by the number of exercise sessions, corrected for the average session duration. Studies that did and did not include pre-exercise cardiac screening were separated to assess any differences in exercise-related event occurrence. This was also performed for studies with exercise prescribed at low, moderate and high levels of claudication pain.

**Risk of bias**

Depending on the research design, bias was assessed using either the ‘Revised Cochrane Risk-of-Bias Tool for Randomised Trials’ or the ‘Risk Of Bias in Non Randomised Studies – of Interventions’ (ROBINS-I). Risk of bias was assessed independently by two reviewers (AW and SS), with disagreements settled with discussion or by a third reviewer (AH). Bias was classified as either low, some concerns, or high.

**Results**

**Study selection**

A search of the literature identified a total of 8693 studies, of which 27 were included in the full review following screening (online supplementary material). Twelve of the included studies were randomised controlled trials, and the remaining 15 were nonrandomised. The included studies comprised a total of 2351 participants, 1642 of whom received a home-based intervention, representing a total of 147,810 patient-hours.

**Participants**

The mean age of participants was 67 ± 2 years, ranging from 64 to 72 years, and, on average, 67% were male. All studies included participants with symptomatic IC. One study also included atypical leg symptoms, such as ischemic leg pain in the buttocks or thigh. In the included studies, common reasons for excluding participants were a walking limitation other than PAD, having had a revascularisation procedure in the last 3 months, foot ulcers, critical limb ischemia, active cancer treatment, an inability to walk unaided, and ischemic pain at rest.

**Study characteristics**

Ten of the included studies were performed in North America, with the remaining studies being conducted across Western Europe (Table 1). Study duration ranged...
| Author (year) | Participants | Age (y) | Male (%) | Study arms | Exercise program | Claudication pain | Programme duration (weeks) | Session frequency (days/week) | Session duration (mins) | Adverse events | Main findings |
|---------------|--------------|---------|----------|-----------|------------------|-------------------|------------------------|-----------------------------|---------------------------|----------------|---------------|
| Gardner (2011) | 119          | 65      | 48       | HBW, SET, usual care | High | 12 | 3 | 42 | 1 myocardial infarction | HBEP and SET groups significantly improved COT (p < 0.001) and PWT (p < 0.01) |
| Gardner (2014) | 180          | 66      | 53       | HBW, SET, light resistance | Low-moderate | 12 | 3 | 38 | None | HBEP and SET groups significantly improved COT, PWT, 6MWD, daily average calisthenics |
| Savage (2001)  | 21           | 66      | 71       | HBW, SET | High | 24 | 3 | 27.5 | None | HBEP and SET groups significantly improved ACD (p < 0.01) |
| McDermott (2013) | 194         | 70      | 50       | HBW, education control | High | 24 | 5 | 50 | I dyspnoea on exercise | HBEP group significantly improved 6MWD (p < 0.001) compared to control group |
| McDermott (2021) | 305         | 69      | 79       | High-intensity HBW, low-intensity HBV | High and low | 52 | 5 | 50 | 1 cardiac arrhythmia, 1 chest pain during exercise | Low-intensity group did not improve 6MWD (p = 0.34), high-intensity group significantly improved (p < 0.001) |
| Sandercock (2007) | 43          | 65      | 74       | HBW, SET, usual care | Moderate | 12 | 3 | 30 | None | SET group significantly improved MWT (p < 0.001) |
| Van Schaarden-burgh (2017) | 29       | 68      | 55       | HBW, calf raises | Low | 8 | 3 | 30 | None | Calf raise group significantly improved PFWD (p = 0.04) and MWD (p = 0.47) |
| Mays (2015) | 25           | 66      | 80       | HBW, walking advice | Moderate | 12 | 3 | 42.5 | None | HBEP group did not improve PWT (p = 0.052) compared to control |
| Regensteiner (1999) | 20         | 64      | NR       | HBW, hospital-based walking | Moderate | 12 | 3 | 42.5 | None | Hospital-based group significantly improved COT, PWT, VO2max (p < 0.05) |
| Collins (2011) | 145          | 66      | 69       | HBW, attention control | NR | 24 | 3 | 50 | None | No significant change in MWD (p = 0.60) |
| Lamberti (2016) | 27           | 69      | 98       | Metronome instructed HBW, revascularisation | Low | 16 | 6 | 20 | None | Both groups significantly improved QoL, ICD, ACD, and PFWD |
| Spafford (2014) | 52           | 65      | 67       | HBW, Nordic pole walking | Low | 12 | 3 | 30 | None | Nordic pole group significantly improved PFWD (p < 0.001) and MWD (p = 0.001) |
| Bronas (2019) | 11           | 65      | 67       | Music guided HBV | Moderate | 12 | 3 | 45 | None | 6MWD significantly improved at 6 weeks (p < 0.001) and 12 weeks (p < 0.001) |
| Cornelis (2021) | 20           | 64      | 75       | HBW and resistance bands | Moderate | 4 | 5 | 30 | None | High participant satisfaction with programme |
| Dinges-biehlner (2002) | 59          | 68      | 64       | HBW, SET, SET with dopiodregel | Moderate | 12 | 7 | 60 | None | All groups significantly improved ICD (p < 0.05); both SET groups improved ACD (p < 0.05) |
| Dopheide (2015) | 40           | NR      | NR       | HBV | Moderate | 52 | 4 | 45 | None | Significantly improved MWD and reduced ROS production (p < 0.01), and increased anti-inflammatory profile (p < 0.0001) |
| Dopheide (2017) | 60           | 68      | 70       | HBW, SET, usual care | Moderate | 28 | 4 | 45 | None | SET group significantly increased femoral artery lumen diameter (p = 0.03) |
| Falkwy (2011) | 217          | 68      | 62       | HBW, supervised exercise | High | 24 | 7 | 30 | None | HBEP group significantly improved PFWD (p = 0.03) and MWD (p < 0.01) |
| Gyldenløve (2019) | 28          | 68      | 67       | HBW | Moderate | 12 | 7 | 30 | None | Significant improvements in PFWD (p = 0.02) and MWD (p = 0.03); no change in SO2 at 12 weeks |
| Imfeld (2006) | 55           | 69      | 62       | HBW, SET, SET with dopiodregel | Moderate | 12 | 7 | 60 | None | All groups significantly improved physical function SF-36 scores |

(Continued)
Table 2. Comparison of complication rates when undertaking a supervised or home-based exercise programme.

| Complication rates | Supervised | Home-based |
|--------------------|------------|------------|
| All-cause          | 1:10,340   | 1:36,953   |
| Cardiac            | 1:13,788   | 1:49,270   |
| Noncardiac         | 1:41,363   | 1:147,810  |

Supervised exercise complication rates taken from Gommans et al.18

Author (year) | Participants (n) | Age (y) | Male (%) | Study arms | Exercise program | Duration (weeks) | Session frequency (days/week) | Session duration (min) | Adverse events | Main findings |
---|---|---|---|---|---|---|---|---|---|---|---|
Lamberti (2021) | 83 | 72 | 78 | Metronome-instructed HBW | Low | 36 | 6 | 16 | None | Significant improvement in PFWD (p < 0.001) but not 6MWD |
Malagoni (2011) | 250 | 70 | 76 | Metronome-instructed HBW | Low | 52 | 6 | 20 | None | Significant improvements in SF-36 domains and walking performance (p < 0.0001) |
Manfredini (2004) | 29 | 66 | 66 | Metronome-instructed HBW | Low | 17 | 7 | 26 | None | Significant improvements in PTS, Smax (p < 0.02) and ABPI (p = 0.01) |
Manfredini (2008) | 126 | 68 | 81 | Metronome-instructed HBW | Low | 24 | 6 | 20 | None | Significant improvement in pain symptoms, ICD and ACD (p < 0.001) |
Mouser (2009) | 120 | 67 | 66 | HBW | High | 24 | 4 | 30 | None | Significant improvements in ICD (p = 0.0001) and ACD (p = 0.006) |
Prévois (2015) | 46 | 60 | 87 | HBW | Low | 24 | 3 | 35 | None | Significant improvement in SF-36 scores (p < 0.05), ICD and ACD (p < 0.01) |
Roberts (2008) | 47 | 67 | 70 | HBW | NR | 12 | 7 | 60 | None | Significant improvement in SF-36 scores (p < 0.05), ICD and ACD (p < 0.01) |

ABPI, ankle-brachial pressure index; ACD, absolute claudication distance; COT, claudication onset time; HBEP, home-based exercise programmes; HBW, home-based walking; ICD, initial claudication distance; MWD, maximum walking distance; 6MWD, 6-minute walk distance; N, not reported; PFWD, pain-free walking distance; PWT, peak walking time; QoL, quality of life; ROS, reactive oxygen species; SET, supervised exercise therapy; SF-36, 36-item short-form survey; Smax, maximum speed; SO2, oxygen saturation; VO2max, maximum oxygen uptake.
data, with an imbalance in reasons for withdrawal in one and a large amount of imputed data in another. Five studies raised some concerns over the possibility of measurement of the outcome being influenced by knowledge of group allocation, as they required judgements from participants aware of their intervention. Three studies were deemed at high risk of bias due to selective reporting, with two missing questionnaire data and one not reporting all time points for treadmill data. One study was deemed at high risk of bias due to unclear group definition, and another raised some concerns as groups were created retrospectively. Two studies raised some concerns over deviations from the intervention, due to an imbalance in medication between groups creating a potential co-intervention and the intervention not being delivered successfully in the majority of participants.

Discussion

The aim of this review was to assess the safety of HBEPs in people living with IC by determining the number of exercise-related adverse events. Previous research has indicated that SET is safe in this population; however, to our knowledge, this is the first study to replicate these methods in HBEPs. In total, there were four related adverse events during 147,000 patient-hours of exercise, resulting in an all-cause event rate of 1 per 36,953 patient-hours.

The all-cause event rate associated with HBEPs was considerably lower than SET, which has previously been reported as 1 per 10,340 patient-hours. Furthermore, the cardiac event rate following HBEPs was lower than in SET (Table 2). There appears to be fewer adverse events after completing a HBEP, despite a potentially greater duration and frequency of training. However, this is likely a result of the exercise being completed at a self-selected pace (despite prescribed intensity), and thus participants may be less likely to experience an exercise-induced event. Despite this, in some cases, the safety of HBEPs may have been overestimated. The number of patient-hours was calculated based on the number and duration of training sessions prescribed. However, not all participants complied with this prescription, which may mean the number of events underrepresents the true risk of full participation. Additionally, owing to the lack of supervision, it is likely that events may have not always been reported by participants.

Gommans et al. determined there were no differences in the number of events when including or not including pre-exercise CPET and ECG; thus, the authors of the review deemed it not to be clinically relevant. Although the American Heart Association recommends exercise testing to identify any exercise-induced coronary ischaemia, existing best practice guidelines do not currently advocate CPETs in those with PAD. In our review, three of the four events occurred in studies employing pre-exercise cardiac screening using ECG. More extensive screening may be more relevant prior to commencing HBEPs than SET, as participants are exercising alone without regular heart rate or blood pressure monitoring. In this case, more care may be needed to account for occult coronary artery disease, which may be exposed following the exercise programme as exercise tolerance improves. However, this was not evident from our analysis, as a lack of screening beforehand did not result in any more adverse events.

Three events were seen following exercise to high claudication pain and the remaining event occurred following pain-free exercise. This may highlight concerns as the expanding literature of HBEPs covers exercise prescribed at a range of claudication pain levels. For example, the current guidelines recommend walking to moderate-maximal claudication pain, and there is increasing interest in programmes prescribing pain-free walking. It is worth noting that by monitoring exercise intensity via claudication pain, higher overall exercise workloads are likely not reached as individuals are symptom-limited before reaching higher equivalents of heart rate or oxygen uptake during which risk may be greater. However, previous research has shown that exercising at heart rates equivalent to claudication pain onset provides a tolerable stimulus that exceeds the anaerobic threshold, thus promoting cardiovascular and metabolic adaptations. This is demonstrated by the majority of included studies having resulted in significant improvements to walking performance. Asymptomatic individuals may be able to reach higher workloads without being limited by claudication pain, and so may be at a greater risk of cardiovascular events than those with classic IC symptoms. This is important when considering the safety of exercise for PAD in the wider population, as classic IC (calf cramp and pain during exertion) is not experiences by all people living with PAD.

Interestingly, despite the exercise programmes in the included studies being described as home-based, the location of the exercise varied. Locations mentioned included: in the home, the community, in a chosen environment, or on an outdoor track, with the majority not giving a clear description. It can be argued that exercise that does not take place inside or within the vicinity of the home (including driveways and gardens) is not home-based. Related adverse events occurring during exercise that do not fall in line with this definition would therefore not represent the safety of a HBEP. Differences in external factors such as the quality of the walking surface, access to areas to sit down, obstacles that exacerbate leg pain, and weather will not be consistent and may potentially influence the risk to the participant’s safety.

Study limitations

This review is not without limitations. The description of exercise programmes was unclear at times making it difficult to ascertain if the programme was really home-based. The accuracy of calculating the total number of patient-hours was impeded by lack of clarity, including some programmes increasing exercise session duration over the course of the programme but not providing specifics. Also, frequency of training was prescribed and reported as a range rather than as a specific number of days per week. Although potentially related adverse events were reported in 14/27 studies, the relatedness was decided by our interpretation on a number of occasions. Therefore, some events we deemed unrelated may in fact have been due to exercise, leading to the potential for...
some misclassification. Not all authors of studies with potentially related events responded to our emails, meaning certain HBEPs which may have altered the results had to be excluded. Additionally, strict participant exclusion criteria likely reduce the ability to generalise the results. As this clinical population trend to be highly co-morbid, an overestimation of the safety of exercise programmes may be potentially harmful. As improvements to exercise tolerance occur, patients may begin to experience previously unseen symptoms of coronary artery disease, presenting further concerns over safety. However, owing to such a low event rate, it is unlikely that the increase in adverse events, when not excluding more at-risk participants, will outweigh the benefits to walking performance, mortality or quality of life seen with exercise programmes. Despite the limitations of our review, we are confident in the findings owing to rigorously following standardised operating procedures and reaching consensus at times of conflict and uncertainty.

Conclusion

The present review adds to existing evidence regarding the safety of exercise in people living with IC. The complication rates associated with HBEPs are lower than those with SET, which were already reported to be extremely low. Given that patients are exercising at home unsupervised, pre-exercise-cardiac screening via CPETs may be more advisable in HBEPs than SET; however, this difference was not discernible from our analysis due to the lack of programmes in this review that included a CPET and a low adverse event rate. Prescribing exercise based on claudication pain level likely means workloads where participants are at greater risk are not reached. Future research should, therefore, assess whether exercise in asymptomatic patients who may be able to tolerate these greater workloads, is as safe as in those with IC.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID IDs

Alexander Waddell https://orcid.org/0000-0002-9880-655X
Sally Seed https://orcid.org/0000-0002-2717-7485
Gordon McGregor https://orcid.org/0000-0001-8963-9107
Stefan T Birkett https://orcid.org/0000-0003-0422-6843
Amy E Harwood https://orcid.org/0000-0002-5745-2564

Supplementary material

The supplementary material is available online with the article.

References

1. Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis. Lancet Glob Health 2019; 7: e1020–e1030.
2. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 1962; 27: 645–658.
3. Gardner AW, Addison O, Katzel LI, et al. Association between physical activity and mortality in patients with claudication. Med Sci Sports Exerc 2021; 53: 732–739.
4. Regensteiner JG, Hiatt WR, Coll JR, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008; 13: 15–24.
5. McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: Associations with the ankle brachial index and leg symptoms. JAMA 2004; 292: 453–461.
6. Gardner AW, Clancy RJ. The relationship between ankle-brachial index and leisure-time physical activity in patients with intermittent claudication. Angiology 2006; 57: 539–545.
7. Gerhard-Herman MD, Gornik HL, Barrett C, et al. AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017; 69: 71–126.
8. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. NICE guidelines [CG147]. https://www.nice.org.uk/Guidance/CG147 (2020, accessed 9 August 2021).
9. Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2017; 12: CD000990.
10. Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: A systematic review and meta-analysis. Sports Med 2015; 45: 231–244.
11. Harwood AE, Smith GE, Broadbent E, et al. Access to supervised exercise services for peripheral vascular disease patients. Ann R Coll Surg Engl 2017; 99: 207–211.
12. Harwood AE, Pymer S, Ibegazene S, et al. Provision of exercise services in patients with peripheral arterial disease in the United Kingdom. Vascular. Published online Aug 4, 2021. DOI: 10.1177/17085381211035259.
13. Divakaran S, Carroll B, Chen S, et al. Supervised exercise therapy for symptomatic peripheral arterial disease among Medicare beneficiaries between 2017 and 2018: Participation rates and outcomes. Circ Cardiovasc Qual Outcomes 2021; 14: e007953.
14. Saxon J, Safley D, Mena-Hurtado C, et al. Adherence to guideline-recommended therapy—including supervised exercise therapy referral—across peripheral artery disease specialty clinics: Insights from the International PORTRAIT Registry. J Am Heart Assoc 2020; 9: e012541.
15. Harwood AE, Broadbent E, Totty JP, et al. ‘Intermittent claudication a real pain in the calf’—Patient experience of diagnosis and treatment with a supervised exercise program. J Vasc Nurs 2017; 35: 131–135.
16. Dua A, Gologorsky R, Savage D, et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. J Vasc Surg 2020; 71: 1702–1707.
17. Pymer SA, Ibegazene S, Palmer J, et al. An updated systematic review and meta-analysis of home-based exercise programmes for individuals with intermittent claudication. J Vasc Surg. Published online Jun 1, 2021. DOI: 10.1016/j.jvs.2021.03.063.
18. Gommans LN, Dekkenrood JJ, Dalen HC, et al. Safety of supervised exercise therapy in patients with intermittent claudication. J Vasc Surg 2015; 61: 512–518.
19. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.

20. Sterne JA, Savovic J, Page MJ, et al. RoB 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019; 366: i4898.

21. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355: i4919.

22. Gardner AW, Parker DE, Montgomery PS, et al. Step-monitored home exercise improves ambulation, vascular function, and inflammation in symptomatic patients with peripheral artery disease: A randomized controlled trial. J Am Heart Assoc 2014; 3: e001107.

23. Gardner AW, Parker DE, Montgomery PS, et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: A randomized controlled trial. Circulation 2013; 123: 491–498.

24. Savage P, Ricci MA, Lynn M, et al. Effects of home versus supervised exercise for patients with intermittent claudication. J Cardiopulmon Rehabil Prev 2001; 21: 152–157.

25. McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: A randomized clinical trial. JAMA 2013; 310: 57–65.

26. McDermott MM, Spring B, Tian L, et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: The LITE randomized clinical trial. JAMA 2021; 325: 1266–1276.

27. Sandercock GR, Hodges LD, Das SK, Brodie DA. The impact of short term supervised and home-based walking programmes on heart rate variability in patients with peripheral arterial disease. J Sports Sci Med 2007; 6: 471–476.

28. Van Schaardenburgh M, Wohlwend M, Rognmo Ø, et al. calf raise exercise increases walking performance in patients with intermittent claudication. J Vasc Surg 2017; 65: 1473–1482.

29. Mays RJ, Hiatt WR, Casserly JP, et al. Community-based walking exercise for peripheral artery disease: An exploratory pilot study. Vasc Med 2015; 20: 339–347.

30. Regensteiner JG, Meyer TJ, Krupski WC, et al. Hospital vs home-based exercise rehabilitation for patients with peripheral arterial occlusive disease. Angiology 1997; 48: 291–300.

31. Collins TC, Lunos S, Carlson T, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: A randomized controlled trial. Diabetes Care 2011; 34: 2174–2179.

32. Lamberti N, Malagoni AM, Cencora A, et al. Experimental model on claudication. Int J Angiol 2018; 13: 201095.

33. Sanderson P, Lefebvre M, Pucheu Y, et al. Training and quality of life. Int Angiol 2004; 23: 379–387.

34. Manfredini F, Malagoni AM, Mascoli F, et al. Training rather than walking: The in-home rehabilitation program for peripheral artery disease patients during the COVID-19 pandemic. Intern Emerg Med 2021; 16: 1307–1315.

35. Malagoni AM, Vagnoni E, Felissatti M, et al. Evaluation of patient compliance, quality of life impact and cost-effectiveness of a “test in – train out” exercise-based rehabilitation program for patients with intermittent claudication. Circ J 2011; 35: 178–184.

36. Lamberti N, Straudi S, Manfredini R, et al. Don’t stop walking: The in-home rehabilitation program for peripheral artery disease patients. Circ J 2008; 72: 946–952.

37. Mouser MJ, Zlabek JA, Ford CL, et al. Community trial of home-based exercise therapy for intermittent claudication. Vasc Med 2019; 14: 103–107.

38. Prévost A, Lafitte M, Pucheu Y, et al. Education and home based training for intermittent claudication: Functional effects and quality of life. Eur J Prev Cardiol 2015; 22: 373–379.

39. Roberts AJ, Roberts EB, Sykes K, et al. Physiological and functional impact of an unsupervised but supported exercise programme for claudients. Eur J Vasc Endovasc Surg 2008; 36: 319–324.

40. Tread-Jacobson D, McDermott M, Beckman J, et al. Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: A Science Advisory from the American Heart Association. Circulation 2014; 104: e700–e710.

41. Harwood AE, Pymer S, Ingle L, et al. Exercise training for intermittent claudication: A narrative review and summary of guidelines for practitioners. BMJ Open Sport Exerc Med 2020; 6: e000897.

42. Mika P, Spodaryk K, Cencora A, et al. Experimental model of pain-free treadmill training in patients with claudication. Am J Phys Med Rehabil 2005; 84: 756–762.

43. Cucato GG, Chehuen MDR, Costa LAR, et al. Exercise prescription using the heart of Claudication pain onset in patients with intermittent claudication. Clinics (Sao Paulo) 2013; 68: 974–978.

44. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: Associated clinical characteristics and functional impairment. JAMA 2001; 286: 1599–1606.

45. Abaraogu U, Ezenwankwo E, Dall P, et al. Barriers to walking in individuals with intermittent claudication: A systematic review to conceptualize a relevant and patient-centered program. PLoS One 2018; 13: 201095.